Gene
FLT3
FLT3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (29), Actionable biomarkers (12), Trial mentions (529), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FLT3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 3 with a planned future start and 10 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 44 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 37 of 8,738 | 0.42% | not measured | |
| 2025 | 32 of 8,875 | 0.36% | not measured | |
| 2024 | 46 of 8,597 | 0.54% | not measured | |
| 2023 | 31 of 8,275 | 0.37% | 78 of 11,460 | 0.68% |
| 2022 | 34 of 8,285 | 0.41% | 82 of 13,598 | 0.60% |
| 2021 | 35 of 8,692 | 0.40% | 88 of 15,045 | 0.58% |
| 2020 | 34 of 7,640 | 0.45% | 83 of 14,459 | 0.57% |
| 2019 | 43 of 7,300 | 0.59% | 66 of 12,159 | 0.54% |
| 2018 | 33 of 6,927 | 0.48% | 68 of 11,854 | 0.57% |
| 2017 | 18 of 6,558 | 0.27% | 62 of 11,595 | 0.53% |
Showing 10 of 37 years.
Assay-provider ledger (29)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Fred Hutchinson Cancer Center | Not a company | Analytical validation | 1 | August 01, 2025 |
| Frederick National Laboratory for Cancer Research | Not a company | Analytical validation | 1 | August 01, 2025 |
| Genexus System (Thermo Fisher) | Context dependent | Analytical validation | 1 | August 01, 2025 |
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 3 | May 14, 2025 |
| Biosharp, China | Reagent supplier | Clinical validationAnalytical validation | 1 | May 14, 2025 |
Showing 5 of 29 assay-provider companies.
Actionable biomarkers (12)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FLT3-ITD | Azacytidine | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| FLT3-ITD | Venetoclax | responsive | acute myeloid leukemia | Cancer Genome Interpreter |
| FLT3 (F691) | Novel Flt3 Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| FLT3-ITD | Flt3 Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| FLT3-ITD | Quizartinib | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
Showing 5 of 12 actionable-biomarker assertions.
Trial mentions (529)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01921998 | Trial biospecimen (AACT) |
| NCT03204838 | Trial biospecimen (AACT) |
| NCT05383014 | Trial biospecimen (AACT) |
| NCT03333486 | Trial eligibility (AACT) |
| NCT01573247 | Trial eligibility (AACT) |
Showing 5 of 529 trial mentions.
Target-disease associations (854)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| ACPA-positive rheumatoid arthritis | immune system disease | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 854 associations.
Vendor sourcing (1,767)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. The variant is located in a mutational hot spot and/or well-established functional domain in which ... | View ClinVar record SCV004013689.1 |
| AGC Biologics S.p.A. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | to be eligible for the study. 1. Written informed consent before any study-related procedure. 2. Adults and children: 1. Adults 18 to 75 (65) years old ... | View trial NCT04097301 |
| AGC Biologics S.p.A. | Trial sponsor | Mentioned in trial textTrial free-text mention | FLT3 | View trial NCT04097301 |
| ARIAD Pharmaceuticals (United States) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients should have a diagnosis of AML (de novo or transformed from hematologic malignancies), MDS or chronic myelomonocytic leukemia (CMML) with one ... | View trial NCT02829840 |
| ARIAD Pharmaceuticals (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | FLT3 | View trial NCT02829840 |
Showing 5 of 1,767 sourcing records.
Trial-cited literature (978)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Quizartinib for Newly Diagnosed <i>FLT3</i>-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | 11 |
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML. | Blood neoplasia | 2026 | 1 |
| Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. | Blood | 2025 | 46 |
| A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. | Cancer chemotherapy and pharmacology | 2025 | 17 |
Showing 5 of 978 papers.
Protein variant mentions (13)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D324N | 1 | 2020 | PMID 32562118 |
| p.D600H | 1 | 2015 | PMID 25730765 |
| p.D835E | 5 | 2009 to 2022 | PMID 35884458, PMID 36050548, PMID 23321257 |
| p.D835V | 6 | 2007 to 2022 | PMID 35884458, PMID 32304015, PMID 23321257 |
| p.F594I | 1 | 2023 | PMID 37147301 |
Showing 5 of 13 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.F594I | BEATAML1.0-COHORT | Myeloid Leukemias; Leukemias, NOS; Unknown; Chronic Myeloproliferative Disorders; Plasma Cell Tumors; Myelodysplastic Syndromes; Hematopoietic and reticuloendothelial systems | 1 | 759 | 0.13% | 0.02% to 0.74% |
| p.F594I | MP2PRT-ALL | Acute Lymphoblastic Leukemia; Lymphoid Leukemias; Hematopoietic and reticuloendothelial systems | 1 | 1,510 | 0.07% | 0.01% to 0.37% |
Literature-extracted relations (281)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Sorafenib | Chemical | negative_correlate |
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. | 2025 |
| cysteine hydrochloride | Chemical | associate |
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. | 2024 |
| Idarubicin | Chemical | negative_correlate |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. | 2023 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. | 2022 |
| Sorafenib | Chemical | negative_correlate |
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. | 2022 |
Showing 5 of 281 relation assertions.
Organizations publishing (670)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 75 | 2009 to 2026 |
| Dana-Farber Cancer Institute | Other | 70 | 2002 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 51 | 2011 to 2025 |
| Government of the United States of America | Government | 41 | 2009 to 2025 |
| Mayo Clinic | Hospital | 36 | 2013 to 2025 |
Showing 5 of 670 organizations.
Where FLT3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
739 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.